LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2-advanced or metastatic breast cancer

被引：0
|
作者：
Hu, Xichun
Wang, Biyun
Wang, Shusen
Tong, Zhongsheng
Sun, Tao
Li, Wei
Song, Lihua
Yan, Xi
Cheng, Ying
Qiu, Fuming
Wang, Xinshuai
Xie, Weimin
Zhao, Bing
Liu, Xinlan
Hu, Changlu
Lai, Guie
Pang, Jinke
Li, Tong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[4] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[5] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[6] First Hosp Jilin Univ, Changchun, Peoples R China
[7] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Jilin Canc Hosp, Changchun, Peoples R China
[10] Zhejiang Univ, Sch Med, Affliated Hosp 2, Hangzhou, Peoples R China
[11] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[12] Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China
[13] Xinjiang Med Univ, Affiliated Tumor Hosp, Urumqi, Peoples R China
[14] Ningxia Med Univ, Gen Hosp, Yinchuan, Ningxia, Peoples R China
[15] Anhui Prov Canc Hosp, Ward Med Oncol 4, Hefei, Peoples R China
[16] Jiangxi Med Coll, Affiliated Hosp 1, Ganzhou, Peoples R China
[17] Genor Biopharma Co Ltd, Shanghai, Peoples R China
[18] Genor Biopharma Co Ltd, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF PALBOCICLIB IN COMBINATION WITH LETROZOLE VERSUS LETROZOLE ALONE FOR PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER HR+ / HER2-IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
    Holanda, P.
    Salgado De Santana, C.
    Senna, T.
    Carmo, L.
    Alexandre, R. F.
    VALUE IN HEALTH, 2021, 24 : S38 - S38
  • [32] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
    Grischke, Eva Maria
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joo Hyuk
    Inoue, Kenichi
    Pivot, Xavier
    Burdaeva, Olga
    Masuda, Norikazu
    Kaufman, Peter
    Koh, Han
    Conte, Pierfranco
    Barriga, Susana
    Hurt, Karla
    Frenzel, Martin
    Johnston, Stephen
    Llombart-Cussac, Antonio
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
  • [33] PATIENT REPORTED HEALTH UTILITY IN HR+/HER2-ADVANCED/METASTATIC BREAST CANCER
    Mitra, D.
    Wood, R.
    De Courcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2016, 19 (07) : A749 - A749
  • [34] First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
    Janni, Wolfgang
    Alba, Emilio
    Bachelot, Thomas
    Diab, Sami
    Gil-Gil, Miguel
    Beck, Thaddeus J.
    Ryvo, Larisa
    Lopez, Rafael
    Tsai, Michaela
    Esteva, Francisco J.
    Zamora Aunon, Pilar
    Kral, Zdenek
    Ward, Patrick
    Richards, Paul
    Pluard, Timothy J.
    Sutradhar, Santosh
    Miller, Michelle
    Campone, Mario
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 169 (03) : 469 - 479
  • [35] Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
    Luis Fein
    Nicolas Lazaretti
    Yamil López Chuken
    J. Rogelio González Ramírez Benfield
    Max S. Mano
    Jose Lobaton
    Ernesto Korbenfeld
    Fernanda Damian
    Dongrui R. Lu
    Ave Mori
    Shem J. Patyna
    Sandra Franco
    Clinical Drug Investigation, 2023, 43 (9) : 707 - 708
  • [36] Phase 3b CompLEEment-1 study of ribociclib plus letrozole in the treatment of HR+/HER2-advanced breast cancer: Final results from the UK cohort
    Tuthill, Mark
    Marwaha, Hardeep
    Hartmann, Christoph E. A.
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2-metastatic breast cancer
    Lambrechts, Yentl
    Hatse, Sigrid
    Kenis, Cindy
    Decoster, Lore
    de Azambuja, Evandro
    Jerusalem, Guy
    Neven, Patrick
    Dal Lago, Lissandra
    Denys, Hannelore
    Vuylsteke, Peter
    Cornelis, Frank
    Punie, Kevin
    Floris, Giuseppe
    Desmedt, Christine
    Laenen, Annouschka
    Ponde, Noam
    Wildiers, Hans
    CANCER RESEARCH, 2023, 83 (05)
  • [38] LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2-locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy
    Xu, Binghe
    Zhang, Qingyuan
    Luo, Yang
    Tong, Zhongsheng
    Sun, Tao
    Shan, Changping
    Liu, Xinlan
    Yao, Yumin
    Zhao, Bing
    Wang, Shusen
    Zeng, Xiaohua
    Hu, Changlu
    Yan, Xi
    Wang, Xiaojia
    Jia, Hongyan
    Chen, Zhendong
    Qiu, Fuming
    Wu, Xinhong
    Zhang, Deyong
    Li, Tong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Lerociclib plus fulvestrant in patients with HR+/HER2-locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial
    Xu, Binghe
    Zhang, Qingyuan
    Luo, Yang
    Tong, Zhongsheng
    Sun, Tao
    Shan, Changping
    Liu, Xinlan
    Yao, Yumin
    Zhao, Bing
    Wang, Shusen
    Zeng, Xiaohua
    Hu, Changlu
    Yan, Xi
    Wang, Xiaojia
    Jia, Hongyan
    Chen, Zhendong
    Qiu, Fuming
    Wu, Xinhong
    Zhang, Deyong
    Li, Tong
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [40] nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
    Hamilton, E.
    Cortes, J.
    Dieras, V.
    Ozyilkan, O.
    Chen, S-C
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Lu, Y.
    Bear, M. M.
    Johnston, E. L.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
12345